Remedy Robotics
Healthcare and physical AI company developing AI-enabled endovascular robotic systems and software for on-premise, remote and autonomous intervention remedyrobotics.com
Funding
- $62 million Series B, announced November 16, 2026. Led by DCVC. New investors include UC Investments, Skip Capital and Hostplus; existing investors Build Collective, Divergent Capital and KdT Ventures also took part. Listed in the AI startup funding roster for November 16–21, 2026. Sources: Remedy Robotics announcement, Cardiovascular Business.
Of the 39 Series B rounds with exactly stated amounts in dollars on Presspool's weekly rosters since September 21, 2026, Remedy Robotics' $62 million is the 14th largest; their median is $55 million.
Whether AI names Remedy Robotics
- Machine Relations Index: Not cited in any Machine Relations Index answer, May 10, 2026 to November 21, 2026.
Related records
Closest rounds in the roster for November 16–21, 2026: Linq ($90M Series B, November 18, 2026), Model ML ($250M Series B, November 17, 2026), Botsync ($11M Series B, November 18, 2026), Promise Robotics (C$40M Series B, November 17, 2026), Numa ($45 million Series C, November 16, 2026), BrightAI ($97M, round type not disclosed, November 18, 2026).
DCVC, which led this round, also led BioStack ($9.5 million Seed, October 22, 2026) and Agility Robotics ($150 million Series B, April 22, 2022). It is also named as an investor in TypeSafe AI ($870 million Series A, October 9, 2026).